HPGC Renmintongtai Pharmaceutical Corp. (600829) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 5.21% and Operating profit at -5.63% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 9.49% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 5.21% and Operating profit at -5.63% over the last 5 years

The company has declared Negative results for the last 4 consecutive quarters

With ROE of 5.10%, it has a fair valuation with a 1.54 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 4,541 Million (Small Cap)

P/E

30.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.38

Return on Equity

5.10%

Price to Book

1.54

Revenue and Profits:

Net Sales:

2,474 Million

(Quarterly Results - Jun 2025)

Net Profit:

27 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

54.27%

6 Months

58.2%

1 Year

74.53%

2 Years

59.75%

3 Years

76.66%

4 Years

117.36%

5 Years

79.83%

HPGC Renmintongtai Pharmaceutical Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.21%

EBIT Growth (5y)

-5.63%

EBIT to Interest (avg)

10.41

Debt to EBITDA (avg)

3.55

Net Debt to Equity (avg)

0.47

Sales to Capital Employed (avg)

2.04

Tax Ratio

26.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

9.08%

ROE (avg)

9.49%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.54

EV to EBIT

24.01

EV to EBITDA

19.01

EV to Capital Employed

1.39

EV to Sales

0.56

PEG Ratio

Dividend Yield

ROCE (Latest)

5.78%

ROE (Latest)

5.10%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -6.90% vs 12.45% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -41.70% vs 527.40% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,474.30",
          "val2": "2,657.80",
          "chgp": "-6.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "60.50",
          "val2": "81.20",
          "chgp": "-25.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.60",
          "val2": "5.90",
          "chgp": "11.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "26.70",
          "val2": "45.80",
          "chgp": "-41.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.30%",
          "val2": "24.80%",
          "chgp": "-0.65%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3.32% vs 7.78% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.00% vs 10.47% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,015.20",
          "val2": "10,359.50",
          "chgp": "-3.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "362.70",
          "val2": "474.30",
          "chgp": "-23.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "35.80",
          "val2": "36.30",
          "chgp": "-1.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.80",
          "val2": "-0.80",
          "chgp": "1,575.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "213.30",
          "val2": "292.20",
          "chgp": "-27.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "30.00%",
          "val2": "39.80%",
          "chgp": "-0.98%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

2,474.30

2,657.80

-6.90%

Operating Profit (PBDIT) excl Other Income

60.50

81.20

-25.49%

Interest

6.60

5.90

11.86%

Exceptional Items

0.00

Consolidate Net Profit

26.70

45.80

-41.70%

Operating Profit Margin (Excl OI)

18.30%

24.80%

-0.65%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -6.90% vs 12.45% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -41.70% vs 527.40% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

10,015.20

10,359.50

-3.32%

Operating Profit (PBDIT) excl Other Income

362.70

474.30

-23.53%

Interest

35.80

36.30

-1.38%

Exceptional Items

11.80

-0.80

1,575.00%

Consolidate Net Profit

213.30

292.20

-27.00%

Operating Profit Margin (Excl OI)

30.00%

39.80%

-0.98%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -3.32% vs 7.78% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.00% vs 10.47% in Dec 2023

All Annual Results

Company CV

About HPGC Renmintongtai Pharmaceutical Corp.

HPGC Renmintongtai Pharmaceutical Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available